The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | 80mg regorafenib plus pembrolizumab for 1L HCC
Richard D. Kim, MD, Moffitt Cancer Center, Tampa, FL, presents updated results from a Phase Ib study of regorafenib 80mg/day or 120mg/day plus pembrolizumab for first-line (1L) treatment of advanced hepatocellular carcinoma (HCC). In this update, first-line regorafenib plus immune checkpoint blockade in advanced HCC demonstrated no new safety signals and encouraging anti-tumor activity. The regorafenib 80mg cohort had lower rates of dose reductions and interruptions due to treatment-related adverse events versus regorafenib 120mg. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
